Nureca Reports Strong Operational Turnaround in Q1 FY’27; Highlights Growth Across Consumer Healthcare Platform
Nureca Limited reported robust financial performance and operational progress for the first quarter of Fiscal Year 2027, indicating a strong turnaround that continued into the new fiscal year. The company emphasized profitable growth, disciplined cost management, and its commitment to expanding its consumer healthcare platform across multiple categories.The results marked a significant period of strength for Nureca, which noted that Q1 FY'27 represented the highest quarterly sales and profitability achieved in the last 16 quarters, marking its strongest performance since Q4 FY 2021-22.
CEO Saurabh Goyal highlighted that manufacturing will remain central to the long-term strategy. The company is focused on expanding capabilities in Punjab to deepen supply chain control and achieve import substitution. Additionally, Dr Trust 360 continues development of its connected-health ecosystem, now integrating AI-powered health insights for users.
Q1 FY’27 Financial Performance Overview
Nureca's consolidated financial performance showed notable sequential and year-over-year improvements in key areas, despite the ongoing focus on building out its diversified consumer healthcare portfolio. The company reported revenues of ₹ 40.3 Crore from operations.The following table details the P&L summary for Nureca Limited (Consolidated):
| Financial Metric (₹ Crore) | Q1 FY 27 | Q4 FY 26 | QoQ % | Q1 FY 26 | YoY % |
|---|---|---|---|---|---|
| Revenue from operations | 40.3 | 35.4 | 14% | 34.2 | 18% |
| Other Income | 1.8 | 1.0 | 80% | 2.6 | -31% |
| Total Revenue | 42.1 | 36.4 | 16% | 36.8 | 14% |
| Total Expenses | 36.9 | 41.1 | -10% | 34.8 | 6% |
| Operating Profits | 3.5 | 2.6 | 35% | -0.6 | 683% |
| EBITDA | 5.2 | -4.7 | 211% | 2.0 | 160% |
| PBT | 4.4 | -5.4 | 181% | 1.3 | 238% |
| PAT | 3.1 | -6.0 | 152% | 0.9 | 244% |
| Gross Margin% | 39% | 40% | -1% | 35% | 4% |
| Operating Margin% | 8.7% | 7.3% | 1.3% | -1.8% | 10.4% |
Growth Drivers and Market Positioning
Nureca continues to leverage its integrated strategy, combining products, distribution, digital health, and manufacturing. The company operates under several key brand ranges across the home-health journey, including Dr Trust Point of Care, Dr Trust Fitness, Dr Physio, Dr Trust Therapy & Recovery, Dr Trust Orthotics, Trumom Mother & Baby, and Dr Trust Healthy Home.From a channel perspective, Ecommerce sales saw an increase of 16% Year over Year (YoY) and 5% Quarter over Quarter (QoQ). The Offline Retail Network revenue trend grew to 57% YoY, with coverage expanding through super stockists and new distributors, showing a 14% QoQ rise.
Manufacturing and Connected Health Ecosystem
The company maintains a manufacturing-led growth model through its NTPL facility in Mohali, focusing on quality and agility. Products manufactured in-house at NTPL include BP monitors, nebulizers, thermometers, massagers, heating pads, orthopaedic cushions and supports, breast pumps, vaporizers, stethoscopes and soft orthopaedic goods. The revenue contribution from these in-house products was 26% for FY 26 and rose to 27% in Q1 FY 27.Furthermore, Dr Trust 360 serves as Nureca's connected-health platform. This ecosystem integrates smart devices, health data, and AI-powered insights, catering to various metrics such as Body Fat and Body Composition for heightened customer engagement.
NURECA Stock Price Movement
Today, shares of Nureca Limited edged higher to close at ₹292.19, climbing 3.73% in the post-market session. The stock maintained solid trading action, moving within a daily range between ₹276 and ₹295.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: